TLX-1423

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTLX-1423
Drug Alias NameNFkappaB inhibitor (Theralogics)NFkappaB inhibitors (Theralogics)NEMO binding peptide (Theralogics)TLX-1423
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInhibitor of NF-kappa-B kinase (IKK) modulatorsNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complexInhibitor of NF-kappa-B kinase (IKK)
Therapy Area/IndicationsReperfusion InjuryInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTheralogics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTheralogics Inc
Active IndicationsN/A
Inactive IndicationsReperfusion InjuryInflammatory Bowel Diseases

Other Information

ATC CodeN/A
Related LinksN/A